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Abstract
Existing mouse models of lethal Ebola virus infection do not reproduce hallmark symptoms of 
Ebola hemorrhagic fever, neither delayed blood coagulation and disseminated intravascular 
coagulation, nor death from shock, thus restricting pathogenesis studies to non-human primates. 
Here we show that mice from the Collaborative Cross exhibit distinct disease phenotypes 
following mouse-adapted Ebola virus infection. Phenotypes range from complete resistance to 
lethal disease to severe hemorrhagic fever characterized by prolonged coagulation times and 100% 
mortality. Inflammatory signaling was associated with vascular permeability and endothelial 
activation, and resistance to lethal infection arose by induction of lymphocyte differentiation and 
cellular adhesion, likely mediated by the susceptibility allele Tek. These data indicate that genetic 
background determines susceptibility to Ebola hemorrhagic fever.
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A mouse-adapted strain of Ebola virus (MA-EBOV) does not cause hemorrhagic syndrome 
despite causing lethal disease in laboratory mice, and cannot be used effectively to study 
Ebola hemorrhagic fever (EHF) pathogenesis, as the dissimilarity to human disease limits 
the ability to identify key correlates of viral pathogenesis or accurately assess the effect of 
vaccines or therapeutics. Pathogenesis studies of EHF have thus been restricted to macaques 
(1–4), guinea pigs (5, 6), and Syrian hamsters (7). Although these models accurately 
recapitulate most of the disease features of EHF, practical and ethical concerns limit their 
use, including non-reproducible genetic backgrounds, cost, animal availability, and reagent 
availability. Epidemiologic studies of EBOV infection have identified a range of pathogenic 
phenotypes, which are not linked to specific mutations in the viral genome (8, 9). This 
suggests that the host response may determine disease severity after EBOV infection.
We tested the role of host genetics in Ebola virus disease (EVD) using the Collaborative 
Cross (CC) resource, a genetically diverse panel of recombinant inbred (CC-RI) mice 
obtained through a systematic cross of eight inbred founder mouse strains, five of which are 
classic laboratory strains (C57BL/6J, A/J, 129S1/SvImJ, NOD/ShiLtJ, NZO/H1LtJ) and 
three of which are wild-derived inbred strains (CAST/EiJ, PWK/PhJ, and WSB/EiJ) (10). 
The founders represent 90% of the common genetic variation across the three major Mus 
musculus subspecies (M. m. musculus, M. m. domesticus, and M. m. castaneus) (11). 
Different strains can be crossed with one another to generate CC-RI intercrossed (CC-RIX) 
F1 progeny. We recently observed a spectrum of pathogenic phenotypes in CC mice, and 
identified genetic loci associated with influenza severity and disease outcome (12, 13). Thus 
we tested whether a similar range of phenotypes would emerge after infecting CC-RIX 
animals with MA-EBOV.
To determine phenotypic baseline, we challenged the eight CC founders intraperitoneally 
with MA-EBOV or the Mayinga strain of wild-type EBOV (WT-EBOV). MA-EBOV 
differs from the published WT-EBOV sequence by only 13 nucleotide changes, three of 
which are silent (14). MA-EBOV is pathogenic in guinea pigs and macaques (1), and causes 
lethal EHF in Syrian hamsters (7). Despite observing 25–100% mortality following MA-
EBOV challenge at multiple doses (Figure S1), we found no evidence of hemorrhagic 
disease or susceptibility to lethal disease after infection with WT-EBOV. We assessed the 
pathogenic phenotype produced by intraperitoneal infection with 100 focus forming units 
(FFU) of MA-EBOV in 47 available CC-RIX lines (Table 1). We observed disease 
phenotypes ranging from complete resistance to lethal disease to severe EHF-associated 
pathology prior to death, as well as lines that lethal infection without symptoms of EHF, but 
sometimes with hepatic discoloration.
We performed detailed studies on two representative lines, 13140×3015 (susceptible to 
lethal EHF) and 15156×1566 (resistant to lethal disease). Mice from both lines lost 
approximately 15% of their body weight over the first five days post-infection (p.i.) (Fig. 
1A). However, susceptible mice succumbed to lethal infection on days 5–6 p.i., while 
resistant mice survived and fully recovered body weight by day 14 (Fig. 1B). At day 5 p.i., 
susceptible mice presented pathological findings consistent with EHF, including prolonged 
blood coagulation, internal hemorrhage, coffee-colored blood, splenomegaly, and hepatic 
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discoloration and softened texture (Fig. 1C). The resistant mice, however, had no evident 
gross pathology at the time of maximum body weight loss and no alteration in the 
appearance of the liver (Fig. 1D). Neither susceptible nor resistant mice developed 
observable clinical disease after challenge with WT-EBOV. We detected extremely low 
titers of virus at day 3 in the liver and spleen of animals following WT-EBOV infection, and 
these were 100–1000-fold lower than organ titers detected in mice infected with MA-EBOV 
(Fig. S2). We did not detect virus at day 5 in any organ or any mouse, indicating that WT-
EBOV is not able to productively replicate in these mouse strains. In liver and spleen from 
both mouse lines, equivalent levels of viral RNA were observed (Figs. 2A,B). However, we 
observed 1–2 logs higher levels of infectious virus in susceptible liver and spleen compared 
to resistant liver and spleen after virus titration by focus forming assay when infectious 
virion production became detectable on day 3 (Figs. 2C,D), suggesting that resistance may 
be associated with a defect in virion assembly, secretion, or other post-transcriptional 
processes. We confirmed this finding by staining liver sections from susceptible and 
resistant mice on day 5 p.i. for VP40, the viral matrix protein. We observed substantially 
less VP40 staining in resistant liver (Fig. 2E,F) compared to susceptible liver (Figs. 2G,H, 
Fig. S3). Sequence analysis showed no nucleotide changes between virus genomes in either 
line, indicating that these effects cannot be readily attributed to selection of quasispecies 
with different viral fitness (Table S1). Despite significant differences in infectious virus 
titers between the two mouse lines, we observed similar levels of inflammation and 
apoptosis in spleen and liver, although the two lines displayed distinct histopathology (Figs. 
S4, S5, S6). Despite similar organ tropism, virus infection occurred in different hepatic cell 
types in the two mouse lines. Susceptible mice had viral antigen in essentially every 
hepatocyte (Fig. 2F, Table S2), while resistant mice viral antigen was restricted to cells that 
lack typical hepatocyte morphology, most likely endothelial cells and Kupffer cells (Fig. 
2G), consistent with low-pathogenicity Reston virus infection (15). Possibly in resistant 
mice, infected hepatic endothelial cell and macrophage responses limit virus production and 
control systemic inflammation and coagulopathy. Widespread hepatic infection in 
susceptible mice may explain how they both produce increased amounts of infectious virus 
and induce dysregulated coagulation pathways.
We quantified the extent of coagulopathy by measuring blood clotting times. On days 5–6 
p.i., susceptible mice showed significantly prolonged thrombin time (TT), prothrombin time 
(PTT), and activated partial thromboplastin time (aPTT) compared to resistant and 
C57BL/6J mice (Fig. 3A–3C). An initial spike in serum fibrinogen levels in susceptible 
mice on day 3 p.i. was followed by a precipitous drop (Fig. 3D) prior to death. This increase 
may be due to compensatory fibrinogen production in response to hepatic cell death and 
consequent clotting factor depletion, consistent with observations in other EHF models in 
which severe hemorrhage and coagulopathy typically peaks within 48 hours preceding death 
(3, 7).
We investigated transcriptional host responses linked to disease outcome in the CC-RIX 
lines. Significant differentially expressed genes relative to time-matched mock-infected 
samples (FDR-adjusted p-value <0.05; fold change > 1.5) in both spleen and liver were 10–
100 fold higher number of DEG in susceptible mice than resistant mice (Fig 4A–B; 
Supplementary Data 2 and 3). These data suggest that EHF is characterized by earlier 
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induction of a larger magnitude transcriptional response. In susceptible mice relative to 
resistant mice, genes associated with EBOV infection were differentially induced. Early in 
infection in the spleens of susceptible mice at day 1 p.i., we observed enrichment of p38 
MAPK and ERK signaling, processes that stimulate productive EBOV infection (16, 17). 
Additionally we observed increased NFkB expression and induction of proinflammatory 
processes, which may reflect early targets of infection in the secondary lymphoid organs. By 
day 3 p.i. in both liver and spleen, inflammatory pathways became increasingly enriched in 
susceptible mice, as did pathways associated with cell death, including those associated with 
cytotoxicity and apoptosis in macrophages and endothelial cells. Both resistant and 
susceptible lines induced multiple immune pathways in the spleen. By day 5, although 
differential gene expression peaked in both lines, the gene sets involved were distinct and 
probably reflect different courses of disease.
We identified differentially expressed genes unique to susceptible mice in liver and 
observed enrichment in genes related to vascular integrity at days 3 and 5, including the 
endothelial tyrosine kinases Tie1 and Tek (Tie2). Tie1 and Tek expression was depressed 
compared with levels in mock-infected animals at day 5, concurrent with the onset of 
coagulopathy. We used Ingenuity Pathway Analysis (IPA) software to generate networks 
predicting molecular activity (18), and predicted activation of processes associated with 
vascular differentiation and endothelial activation, IL-6-mediated inflammation, and 
bleeding, and inhibition of pathways associated with vascular integrity and inflammatory 
regulation in susceptible livers (Fig. S7). TIE1 and TEK signaling promote activation of 
coagulation factors, such as thrombin (F2), tissue factor (F3), and protease activated 
receptors 1, 3, and 4 (PAR1/F2R, PAR3/F2RL2, PAR4/F2RL3) (19), which have been 
mechanistically implicated in coagulopathies mediated by EBOV and other viruses (4, 20), 
and are differentially regulated in these mice (Fig. S8). Tie1 and Tek expression was 
consistently elevated in resistant mouse spleens, implying that endothelial signaling 
regulation and vascular leakage contributes to disease resistance in susceptible mice. In 
livers from resistant mice at day 5, gene expression associated with vascular density and 
angiogenesis increased, suggesting that this line effectively controls vascular leakage, 
potentially through repair or structural maintenance of blood vessels. It seems likely that 
restriction of MA-EBOV infection to endothelial and Kupffer cells in resistant mice 
prevents induction of hepatocyte-specific molecules that enhance systemic inflammation, 
thrombocytopenia, and coagulopathy.
We investigated the genomes and found that the Tie1 alleles across the eight CC founders 
are from all three Mus musculus subspecies, and are highly divergent from one another (21), 
which prevented us from identifying significant relationships between Tie1 alleles and 
phenotype. In contrast, Tek alleles in the CC-RIX are derived from only two subspecies: M. 
m. domesticus and M.m. musculus, and are very different from one another. Distinct Tek 
alleles were previously associated with inflammatory coagulopathies and vascular 
dysfunction (22–26). In our preliminary analysis, we identified statistically significant 
relationships between subspecific Tek alleles and initial onset of weight loss (ANOVA, 
F2,31=5.581, p=0.0085), average day of death (ANOVA F2,34=10.519, p=0.00028), and 
mortality (ANOVA F2,37=8.5553, p=0.0008) (Fig. S9). Here, we reproduced EHF in a 
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mouse model that will allow linkage of specific genetic polymorphisms to tropism, 
infectious virus production, cell type-specific responses, and phenotypic outcome. The CC 
model provides a unique platform to map susceptibility alleles in the context of EHF 
pathogenesis, and rapidly apply these findings to the development of candidate therapeutics 
and vaccines. Ongoing screening activities in CC-RIX mice will identify additional genetic 
loci that contribute to hemorrhagic disease, lethality, or resistance to severe disease.
The frequency of different pathological manifestations across the 47 CC-RIX lines screened 
so far are similar in variety and proportion to the spectrum of clinical disease observed in 
patients with Ebola virus disease in the 2014 West Africa outbreak, with hemorrhagic 
symptoms appearing in 30–50% of patients (27, 28). Although we cannot rule out the 
possibility that human survivors have pre-existing immunity to EBOV or a related virus, our 
data suggest that genetic factors play a significant role in determining disease outcome in 
naïve individuals without prior exposure or immunologic priming.
While we have not yet screened CC-RIX mice for susceptibility to other ebolavirus species, 
we anticipate that we would observe a similar distribution of pathogenic phenotypes 
following infection with viruses that are capable of replicating in mice. The current 2014 
West Africa outbreak is caused by the same species of ebolavirus as the MA-EBOV used in 
this screen. There are also similarities in the spectrum of disease observed in CC-RIX mice 
infected with MA-EBOV and in clinical cases in the current outbreak. The model described 
in this paper can be implemented promptly to identify genetic markers, conduct meticulous 
pathogenesis studies, and evaluate therapeutic strategies that have broad-spectrum antiviral 
activity against all Zaire ebolaviruses, including the virus responsible for the current West 
Africa outbreak.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Distinct Morbidity and Mortality Following MA-EBOV Infection in CC-RIX Mouse 
Lines
A. Percent of starting body weight over course of infection in susceptible (red squares) and 
resistant mice (blue circles). Data shown are mean ± SEM from five mice per CC-RIX line. 
B. Kaplan-Meier survival curve for susceptible (red) and resistant (blue) mice. Five mice 
were used for each CC-RIX line. C,D,E,F. Gross appearance of liver at necropsy in 
uninfected susceptible (C) and resistant (E) mice, and on day 5 post-infection in susceptible 
(D) and resistant (F) mice.
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Figure 2. MA-EBOV Replication in CC-RIX Mouse Lines
A,B. Quantitative real-time PCR showing expression of MA-EBOV genomes relative to 
mouse 18S rRNA in spleen (A) and liver (B). Data shown are mean ± SEM for three mice 
per time point per RIX line. C,D. Titration of infectious MA-EBOV in organ homogenates 
from spleen (C) and liver (D) quantified as focus forming units per milliliter. No infectious 
virus was detected prior to day 3 p.i. Data shown are mean ± SEM from two experiments 
using 2–3 mice per time point per CC-RIX line. E,F,G,H. Immunohistochemical staining 
for VP40 in resistant liver (E,F) and susceptible liver (G,H). Arrow indicates representative 
hepatocyte morphology. (t-test, *p<0.05)
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Figure 3. Quantification of Coagulopathy and Hemorrhage in CC-RIX Mouse Lines
A,B,C. Coagulation times in seconds for thrombin (A), prothrombin (B), and activated 
partial thromboplastin (C) over course of MA-EBOV infection. D. Serum fibrinogen levels 
in CC-RIX mice over course of MA-EBOV infection. All data shown are the mean ± SEM 
for 2 experiments including 2–5 animals per time point. (ANOVA with Tukey’s HSD post-
hoc. *p<0.05, **p<0.05, ***p<0.0000001).
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Figure 4. Distinct Host Responses Associated with Disease Phenotype
A,B. Number of differentially expressed genes (DEG) either up-regulated (positive y-axis) 
or down-regulated (negative y-axis) relative to time-matched mock-infected samples in 
spleen (A) and liver (B).
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Table 1
Distribution of Phenotypes Across CC-RIX Lines
Outcome of Infection Frequency of 
phenotype (%)
Phenotypic characteristics CC-RIX line ID Mortality (%)
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Outcome of Infection Frequency of 
phenotype (%)













Boldface type indicates CC-RIX crosses used in this study
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